EWTX · Edgewise Therapeutics, Inc. · Metrics
$39.91
-1.27 (-3.07%)
At close · Nov 20
Return incl. dividend (before tax)
Market Cap
$4.37B
Shares
109.48M
Volume · Nov 20
1.19M
Avg daily vol (3M)
1.53M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
EWTX metrics
72 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$39.91
Market cap
$4.37B
Price action
23 metricsPrice change (1W)
-13.1%
Price change (30D)
+1.5%
Price change (3M)
-9.7%
Price change (6M)
+22.0%
Price change (YTD)
+60.8%
Price change (1Y)
+79.3%
Trailing year
Price change (5Y)
+100.1%
52-week high
$48.74
52-week low
$20.94
Change from 52-week high
-18.1%
Change from 52-week low
+90.6%
Annualized volatility
72.7%
Annualized volatility (3M)
54.1%
Implied volatility (30D)
97.4%
IV rank (1Y)
25.8
IV percentile (1Y)
77.3
Beta
1.2
RSI (14D)
44.2
Price vs SMA 50
-3.0%
Price vs SMA 200
+6.9%
Avg volume (3M)
1.53M
Relative volume
0.8
Average dollar volume
$63.79M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
109.48M
Valuation
12 metricsP / E (TTM)
4.9
Trailing earnings · reciprocal yield 20.5%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.7
reciprocal yield 37.4%
FCF yield
-4.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
23.1%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2024-05-13
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$218.18M
Net income (TTM)
$1.01B
Trailing 12 months
Diluted EPS (TTM)
$8.19
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+14.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
61.8%
Return on assets
56.7%
Debt / equity
0.0
Current ratio
12.3
EBITDA (TTM)
—
Free cash flow (TTM)
−$202.28M
Quick ratio
12.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$68.68M
Latest balance sheet
Cash & equivalents
$68.68M
Total assets
$1.78B
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$201.90M
Capital expenditures (TTM)
$382,000
R&D (TTM)
$165.37M
SG&A (TTM)
—
Stock compensation (TTM)
$36.52M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
253
13F filer change QoQ
+27
Institutional ownership
114.2%
Conviction holders (share of 13F filers)
5.9%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.7%
Holder tenure
14.0
Price vs estimated holder cost
+63.4%
Ownership (registered funds)
1 metricsIndex-fund ownership
10.3%
Short interest
3 metricsShort interest
11.6%
Latest settlement · 9.6 days to cover
Days to cover
9.6d
Short-squeeze score
72 / 100
Insider activity
2 metricsNet insider buying (90D)
−$240,627
Insider-sentiment score
45 / 100
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1710072
CUSIP
28036F105
13F (30d)
260 filings
237 filers
Visit website
Investor relations